Medistim

Regulatory Filings • Feb 19, 2015

Medistim has received clearance for sale of VeriQ C in China

Medistim has received clearance for sale of VeriQ C in China

(Oslo, February 19th, 2015) Medistim ASA (OSE:

MEDI), a Norwegian company that develops and

commercializes medical equipment for use within

cardiac, vascular and transplant surgery, announces

that they have received clearance from the China

Food and Drug Administration (CFDA) for sale of its

product VeriQ C

VeriQ C represent Medistim's most advanced

intraoperative model for quality assessment used

during coronary artery bypass grafting (CABG). The

system combines state-of-art transit time blood flow

measurements (TTFM) with an ultrasound imaging

modality. By using ultrasound imaging, it will

become easier for the surgeon to plan, optimize and

assess quality of the surgical procedure. VeriQ C is

a unique tool that can contribute to improved

surgical precision and quality, which may ultimately

provide better outcomes for the patients.

In addition to CABG, the VeriQ C may be applied in

other surgical areas, such as valve surgery, surgery

of congenital heart defects, transplant surgery and

vascular surgery.

Medistim has already obtained clearance from the US

Food and Drug Administration (FDA), the CE

certificate in Europe and the clearance for sale in

Japan and Canada. Medistim is now positioned to

sell the VeriQ C in all its major markets.

Globally, about 700 000 coronary artery bypass graft

(CABG) procedures and 600.000 vascular procedures

are being performed every year. China represents a

significant market opportunity for Medistim with

about 35.000 CABG procedures performed per year and

a projected annual growth rate of 10 %.Today,

Medistim covers about 30 % of these procedures with

its traditional flow measurement system

VeriQ "Medistim is well positioned for further

growth in China, with a number of systems placed

with the largest cardiac centers and supported by

leading Chinese surgeons, says Kari E. Krogstad,

President and CEO in Medistim ASA and

continues: "Finally we can offer our premium

products to the Chinese market. There is already a

growing interest for the combination of ultrasound

imaging and TTFM measurements amongst surgeons in

China, and the future outlook is good."

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track

record of profitable growth over the past >10

years. The company is a pioneer within its segment,

and continues to invest in new product development.

Medistim has wholly owned subsidiaries with sales

organizations in the US, Germany, Denmark, UK and

Norway, in addition to the about 50 distributors in

Europe, Asia, Middle East, Africa and South

America. For more information, visit the Medistim

home page:www.Medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).